Increasing numbers of us use it, but mouthwash can actually make bad breath even WORSE
Jun 18, 2013 by CB
Write comment
Data from the Phase III EMILIA study, presented at the European Society for Medical Oncology (ESMO) show that T-DM1 (trastuzumab emtansine) prolongs the lives of patients with advanced HER2-positive breast cancer when compared with the only approved licensed treatment combination, lapatinib and capecitabine, (30.9 months vs. 25.1 months, HR=0.682; P=0.0006), while significantly reducing the side effects of chemotherapy.1 T-DM1 is expected to gain a licence for use in the UK late 2013…
Read more:
http://www.medicalnewstoday.com/releases/251007.php